These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 21128878

  • 1. Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
    Song X, Zhao Z, Barber B, Gregory C, Wang PF, Long SR.
    Curr Med Res Opin; 2011 Jan; 27(1):123-30. PubMed ID: 21128878
    [Abstract] [Full Text] [Related]

  • 2. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
    Zhao Z, Pelletier E, Barber B, Bhosle M, Wang S, Gao S, Klingman D.
    Curr Med Res Opin; 2012 Feb; 28(2):221-9. PubMed ID: 22171947
    [Abstract] [Full Text] [Related]

  • 3. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [Abstract] [Full Text] [Related]

  • 4. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
    Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A.
    Oncologist; 2012 Oct; 17(12):1486-95. PubMed ID: 23015662
    [Abstract] [Full Text] [Related]

  • 5. Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.
    Grothey A, Marshall JL.
    Oncology (Williston Park); 2007 Apr; 21(5):553-64, 566; discussion 566-8, 577-8. PubMed ID: 17536342
    [Abstract] [Full Text] [Related]

  • 6. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [Abstract] [Full Text] [Related]

  • 7. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C.
    J Clin Oncol; 2012 Oct 01; 30(28):3499-506. PubMed ID: 22949147
    [Abstract] [Full Text] [Related]

  • 8. [Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].
    Abe H, Mafune K, Minamimura K, Abe M, Umemura A, Hirata T.
    Gan To Kagaku Ryoho; 2013 May 01; 40(5):601-4. PubMed ID: 23863581
    [Abstract] [Full Text] [Related]

  • 9. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Taïeb J, Artru P, Paye F, Louvet C, Perez N, André T, Gayet B, Hebbar M, Goebel FM, Tournigand C, Parc R, de Gramont A.
    J Clin Oncol; 2005 Jan 20; 23(3):502-9. PubMed ID: 15659495
    [Abstract] [Full Text] [Related]

  • 10. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L, Fielding A, Robertson JD, Saunders MP.
    J Clin Oncol; 2012 Oct 10; 30(29):3596-603. PubMed ID: 22965965
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
    Hebbar M, Tournigand C, Lledo G, Mabro M, André T, Louvet C, Aparicio T, Flesch M, Varette C, de Gramont A, Oncology Multidisciplinary Research Group (GERCOR).
    Cancer Invest; 2006 Mar 10; 24(2):154-9. PubMed ID: 16537184
    [Abstract] [Full Text] [Related]

  • 12. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
    Liu JH, Hsieh YY, Chen WS, Hsu YN, Chau GY, Teng HW, King KL, Lin TC, Tzeng CH, Lin JK.
    Int J Colorectal Dis; 2010 Oct 10; 25(10):1243-9. PubMed ID: 20574727
    [Abstract] [Full Text] [Related]

  • 13. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J.
    J Clin Oncol; 2007 Oct 20; 25(30):4779-86. PubMed ID: 17947725
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
    Hsu HC, Chou WC, Shen WC, Wu CE, Chen JS, Liau CT, Lin YC, Yang TS.
    Anticancer Res; 2013 Aug 20; 33(8):3317-25. PubMed ID: 23898098
    [Abstract] [Full Text] [Related]

  • 15. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
    Huang MY, Huang ML, Chen MJ, Lu CY, Chen CF, Tsai PC, Chuang SC, Hou MF, Lin SR, Wang JY.
    Pharmacogenet Genomics; 2011 Jan 20; 21(1):18-25. PubMed ID: 21057378
    [Abstract] [Full Text] [Related]

  • 16. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M.
    Cancer Biomark; 2009 Jan 20; 5(4):167-75. PubMed ID: 19729826
    [Abstract] [Full Text] [Related]

  • 17. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
    Hong YS, Kim HO, Kim KP, Lee JL, Kim HJ, Lee SJ, Lee SJ, Oh SJ, Kim JS, Ryu JS, Moon DH, Kim TW.
    J Nucl Med; 2013 Aug 20; 54(8):1209-16. PubMed ID: 23804324
    [Abstract] [Full Text] [Related]

  • 18. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
    Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P.
    BMC Cancer; 2009 Sep 28; 9():347. PubMed ID: 19785749
    [Abstract] [Full Text] [Related]

  • 19. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
    Iveson T, Carter AM, Shiu KK, Spooner C, Stevens D, Mullamitha S.
    BMC Cancer; 2020 Feb 03; 20(1):91. PubMed ID: 32013902
    [Abstract] [Full Text] [Related]

  • 20. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
    Innocenti F, Sibley AB, Patil SA, Etheridge AS, Jiang C, Ou FS, Howell SD, Plummer SJ, Casey G, Bertagnolli MM, McLeod HL, Auman JT, Blanke CD, Furukawa Y, Venook AP, Kubo M, Lenz HJ, Parker JS, Ratain MJ, Owzar K.
    Clin Cancer Res; 2021 Jan 01; 27(1):267-275. PubMed ID: 32958699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.